Recent studies have identified potentially clinical roles of MAP3K3 as an oncogene that promotes cancer progression in several different malignancies including non‐small‐cell lung cancer, ovarian carcinoma, lung cancer and renal clear cell carcinoma 14, 21, 22, 23. This evidence concerns the gene MAP3K3 and ovarian carcinoma.